Neuroimaging in Clinical Trials for Huntington’s Disease: Emerging Research Findings: The Advancement Directions and Implications

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 02 | 02 | Page : –
    By

    Vinod B Bhamare,

  • Sandip S Patil,

  1. Research Scholar, Department of Computer Engineering, S. S. B. T. COLLEGE of ENGINEERING & TECHNOLOGY at Bambhori, Jalgaon, India, Jalgaon, India
  2. Associate Professor, Department of Computer Engineering, S. S. B. T. COLLEGE of ENGINEERING & TECHNOLOGY at Bambhori, Jalgaon, India, Jalgaon, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_193286’);});Edit Abstract & Keyword

Neuroimaging is very important in coordinating and conducting Huntington’s disease clinical trials as a tool in selecting patients, managing safety concerns, and assessing the benefits of interventions. This review presents the current uses and potential future uses of structural and functional magnetic resonance imaging (MRI), diffusion imaging, positron emission tomography (PET), proton magnetic resonance spectroscopy (MRS), perfusion imaging, and magneto encephalography (MEG) in HD trials. We describe how these modalities contribute to patient selection, biomarker optimization, and pharmacokinetic studies, as well as documenting disease amelioration and neuroplastic changes after treatment. Furthermore, they explore the difficulties of adapting neuroimaging approaches from research to clinical settings in relation to technical standardization, patient burden, costs for equipment, and difficulties of data interpretation. By critiquing, we identify novel developments in neuroimaging methods and discuss ways to enhance their application in HD trials. The review closes by highlighting the role of neuroimaging, in general, to improve patient prognosis and boost research in HD therapeutic interventions if implemented with precise modalities and research study designs. Huntington’s disease (HD), Neuroimaging/clinical research, Drug trials, Magnetic resonance imaging (MRI), Positron emission tomography (PET), Magnetoencephalography (MEG), Patient subgrouping/characterization, Disease prevention and brain reorganization.

Keywords: Huntington’s disease (HD), Neuroimaging, Clinical trials, Magnetic resonance imaging (MRI), Positron emission tomography (PET), Magnetoencephalography (MEG), Patient stratification, Disease modification, Brain reorganization

How to cite this article:
Vinod B Bhamare, Sandip S Patil. Neuroimaging in Clinical Trials for Huntington’s Disease: Emerging Research Findings: The Advancement Directions and Implications. International Journal of Brain Sciences. 2025; 02(02):-.
How to cite this URL:
Vinod B Bhamare, Sandip S Patil. Neuroimaging in Clinical Trials for Huntington’s Disease: Emerging Research Findings: The Advancement Directions and Implications. International Journal of Brain Sciences. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijbs/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_193286’);});Edit

References

  1. The Huntington’s Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72(6), 971–983.

  2. Ghosh, R., & Tabrizi, S. J. (2018). Clinical features of Huntington’s disease. In Advances in Experimental Medicine and Biology (Vol. 1049, pp. 1–28).

  3. Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., et al. (2022). Potential disease-modifying therapies for Huntington’s disease: Lessons learned and future opportunities. The Lancet Neurology, 21(7), 645–658.

  4. Kaplan, S., Itzkovitz, S., & Shapiro, E. (2007). A universal mechanism ties genotype to phenotype in trinucleotide diseases. PLoS Computational Biology, 3(11), e235.

  5. Schwarz, A. J. (2021). The use, standardization, and interpretation of brain imaging data in clinical trials of neurodegenerative disorders. Neurotherapeutics, 18(2), 686–708.

  6. McGowan, J. C. (2008). Basic principles of magnetic resonance imaging. Neuroimaging Clinics of North America, 18(4), 623–636.

  7. Tabrizi, S. J., Reilmann, R., Roos, R. A., Durr, A., Leavitt, B., Owen, G., … & TRACK-HD Investigators. (2019). Potential disease-modifying therapies for Huntington’s disease: Progress and challenges. The Lancet Neurology, 18(11), 1015–1026.

  8. Paulsen, J. S., Long, J. D., Ross, C. A., & PREDICT-HD Investigators. (2014). Brain atrophy in early Huntington’s disease: Evidence from PREDICT-HD study. Journal of Neurology, Neurosurgery & Psychiatry, 85(12), 1231–1239.

  9. Estevez-Fraga, C., Scahill, R. I., & Tabrizi, S. J. (2020). Diffusion MRI metrics in Huntington’s disease: A review of applications and limitations. Journal of Neuroimaging, 30(4), 461–471.

  10. Poudel, G. R., Stout, J. C., Domínguez, D. J., & Churchyard, A. J. (2014). Functional changes in the cortico-striatal network in early Huntington’s disease: An fMRI study. Brain Imaging and Behavior, 8(4), 540–552.

  11. Sturrock, A., & Leavitt, B. R. (2015). The potential of PET imaging in Huntington’s disease clinical trials. Journal of Huntington’s Disease, 4(3), 239–251.

  12. Cozzi, L., Zago, S., & Tabrizi, S. J. (2020). Insights from magnetic resonance spectroscopy in Huntington’s disease. Neurobiology of Disease, 144, 105018.

  13. Scahill, R. I., Zeun, P., Osborne-Crowley, K., Johnson, E. B., Gregory, S., Parker, C., … & Tabrizi, S. J. (2020). Biological and clinical impact of genetic variability in Huntington’s disease: An MRI-based study. Nature Communications, 11(1), 1–13.

  14. Gregory, S., Crawford, H., & Tabrizi, S. J. (2015). Multi-modal neuroimaging in Huntington’s disease: A future perspective. Journal of Neurology, 262(6), 1463–1474.

  15. Tabrizi, S. J., Reilmann, R., Roos, R. A., Durr, A., Leavitt, B. R., Owen, G., … & Langbehn, D. R. (2019). Potential clinical and neuroimaging biomarkers in Huntington’s disease: A prospective study. Nature Reviews Neurology, 15(4), 235–247.

Ahead of Print Subscription Review Article
Volume 02
02
Received 04/04/2025
Accepted 22/05/2025
Published 26/05/2025
Publication Time 52 Days
84

[first_name] [last_name]

My IP

PlumX Metrics